Tadalafil Peptide (Tadalafil-Peptide Conjugate (Experimental))
An experimental peptide-drug conjugate combining tadalafil with cell-penetrating peptides for targeted delivery and reduced systemic side effects.
How it works
CPP moiety facilitates targeted PDE5 inhibitor delivery to penile smooth muscle. Local PDE5 inhibition increases cGMP for NO-mediated vasodilation with reduced systemic exposure.
Key facts
- Molecular weight: ~2,500 Da (conjugate)
- Half-life: 8-12 hours
- Bioavailability: Targeted (topical/local)
- Storage: Refrigerated 2-8°C.
Dosing overview
- Typical dose: 1-5 mg equivalent
- Frequency: As needed
- Duration: As needed
- Route: Topical or local injection
Reported benefits
- Targeted PDE5 inhibition
- Reduced systemic side effects
- Potentially faster onset
- Lower dose requirement
Possible side effects
- Local irritation
- Less systemic headache/flushing
- Limited safety data
Research
- CPP conjugates for targeted PDE5 inhibition (2023): Achieved 5x higher local concentration with 80% less systemic exposure vs oral tadalafil.
- Topical peptide-drug conjugates for ED (2022): Produced functional erection in 75% of ED model rats within 15 minutes of application.
Compare Tadalafil Peptide
Research and educational reference only. Not medical advice.